|Day Low/High||9.03 / 9.62|
|52 Wk Low/High||9.44 / 22.40|
The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
Use long-dated calls to take some of risk out of this inherently high-beta space.
These companies will benefit immensely as the country experiences a burst of economic growth.
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
Some acceleration in losses across the major indices since out last update. With options expiration today, we could see some volatility in the last hour of trading. My covered calls referenced in a previous post have not hit yet but have a good chan...
Pre-market futures are now pointing to a slightly down open. Bank stress test have the financial sector under pressure as the Financial Select Sector SPDR ETF is down over 1% close to the opening bell. Zogenix should have a good day. The FDA approve...
Merger activity is the number 1 driver I am watching for biotech growth.
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
The market has strengthened a bit since our last update. T2 Biosystems is now up over 50% on positive developments that we chronicled in my last post. Lexicon Pharmaceuticals is up some 30% today off oversold levels. It should receive some $260 mil...
Markets continue to be nicely in the black two hours into trading as resumption of U.S.-China trade talks have investors in a good mood to start off the second half of trading in 2019. Some small biotechs continue to show some strength this Monday. ...
Knowing when to continue to fish or cut bait is something that develops over time in this space.
Here are updates on small biotech/biopharma names I have profiled before.
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
Materials and technology names led the way down on the session.
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...
Only one fund category (of 20) has beaten the S&P 500 over half a decade.